Journal
CANCER CELL
Volume 41, Issue 1, Pages 106-+Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.11.014
Keywords
-
Categories
Ask authors/readers for more resources
Immune checkpoint blockade (ICB) has revolutionized cancer therapy by promoting effective immune responses through the activation of CD4(+) T cells and the recruitment of eosinophils. This study demonstrates the critical role of eosinophils in ICB response and provides proof-of-principle for enhancing ICB efficacy through eosinophil engagement. Mechanistically, ICB increases IL-5 production, stimulating elevated eosinophil production and systemic eosinophil expansion.
Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer. We observe an increase in systemic and intratumoral eosinophils in patients and mice responding to ICB treatment. Mechanistically, ICB increased IL-5 production by CD4(+) T cells, stimulating elevated eosinophil production from the bone marrow, leading to systemic eosinophil expansion. Additional induction of IL-33 by ICB-cisplatin combination or recombinant IL-33 promotes intratumoral eosinophil infiltration and eosinophil-dependent CD8(+) T cell activation to enhance ICB response. This work demonstrates the critical role of eosinophils in ICB response and provides proof-of-principle for eosinophil engagement to enhance ICB efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available